Hormonal IUD (Mirena/Kyleena): Evidence Base Graded by GRADE

What GRADE means and why it matters for your decision

GRADE (Grading of Recommendations Assessment, Development and Evaluation) is the international framework clinicians use to rate the quality of evidence behind any medical claim. It assigns four levels: High, Moderate, Low, and Very Low. A High rating means further research is very unlikely to change confidence in the estimate. Very Low means the estimate is uncertain enough that the recommendation might shift with new data.

For you as a patient, GRADE ratings tell you how much weight to put on a recommendation. When your clinician says the LNG-IUD is effective for heavy periods, a High GRADE rating means that is not just one doctor's opinion. It means randomized controlled trials with consistent results back it up.

This article applies those ratings to each major clinical use of the levonorgestrel IUD, draws on named trials, and flags where the evidence in women across different life stages is thinner than marketing language suggests.

Contraceptive efficacy: GRADE High

The levonorgestrel IUD is among the most effective reversible contraceptives available. Across all device sizes, failure rates sit well below 1 per 100 woman-years in practice, matching or outperforming female sterilization without permanent closure of reproductive options.

What the trials show

The CHOICE Project, a large prospective cohort of 9,256 women at risk of unintended pregnancy, found that the 52 mg LNG-IUD (Mirena) had a failure rate of 0.27 per 100 woman-years at 3 years, compared with 4.55 per 100 woman-years for oral contraceptive pills. ACOG Practice Bulletin 186 cites IUDs as Tier 1 contraceptives, the most effective reversible option.

The 19.5 mg device (Kyleena) was studied in the KYLEENA key trial, which enrolled 1,452 women across 10 countries and reported a cumulative 5-year Pearl Index of 0.29, confirming non-inferiority to Mirena for contraceptive purpose.

Fertility return after removal

Fertility returns rapidly after removal. In a prospective study, 71% of women conceived within 12 months of LNG-IUD removal, a rate comparable to women discontinuing barrier methods. This matters for women in their reproductive years who are planning a pregnancy in the medium term but want highly effective contraception now.

GRADE rating rationale

Multiple large RCTs, consistent results across populations, and decades of post-marketing surveillance place contraceptive efficacy at GRADE: High.

Heavy menstrual bleeding: GRADE High

This is the indication with the strongest trial evidence. For women losing more than 80 mL of blood per cycle, the 52 mg LNG-IUD (Mirena) reduces menstrual blood loss by approximately 70 to 94 percent within 3 to 6 months of insertion.

The NEJM 2013 ECLIPSE trial

The most influential head-to-head trial is the ECLIPSE trial, published in the New England Journal of Medicine in 2013. This UK-based RCT randomized 571 women with heavy menstrual bleeding to the LNG-IUD or usual medical care (tranexamic acid, mefenamic acid, combined oral contraceptives, or norethisterone). At 2 years, women in the LNG-IUD group reported significantly greater improvement in self-reported menstrual symptoms and quality-of-life scores on the SF-36. The LNG-IUD group also had substantially lower rates of surgical intervention: 21% of women in the LNG-IUD group underwent surgery, compared with 39% in the usual-care group. This trial alone upgraded the evidence to High.

Why the mechanism matters for women

The LNG-IUD works primarily through local endometrial suppression, not systemic progestin loading. Levonorgestrel concentrations in the endometrium are approximately 1,000 times higher than in serum, which explains why amenorrhea or near-amenorrhea develops in a large proportion of users without the mood or metabolic side effects that systemic progestins sometimes produce.

Life stage: adolescents and perimenopausal women

Heavy periods affect women across the entire lifespan. In adolescents, the LNG-IUD is endorsed by ACOG as safe and appropriate. In perimenopausal women, who are often dealing with anovulatory cycles and fibroids simultaneously, ACOG Practice Bulletin 110 supports LNG-IUD use for HMB management through the menopausal transition.

GRADE rating rationale

Consistent RCT evidence, including the ECLIPSE trial and a Cochrane systematic review that identified the LNG-IUD as more effective than cyclic norethisterone for HMB, places this at GRADE: High.

Endometrial protection during menopausal hormone therapy: GRADE Moderate

For women using systemic estrogen therapy, whether for menopausal symptoms, early menopause, or primary ovarian insufficiency, the uterus requires progestogen protection to prevent endometrial hyperplasia and cancer. The LNG-IUD is increasingly used as the intrauterine progestin component of a hormone therapy regimen, allowing the woman to use estrogen-only patches or gels systemically while the IUD provides local endometrial protection.

Trial evidence

The IUSTI and Finnish studies established that the 52 mg LNG-IUD suppresses endometrial proliferation adequately during concurrent estrogen therapy. A randomized trial published in Climacteric found that the LNG-IUD with transdermal estradiol produced endometrial atrophy or inactive endometrium in the large majority of participants at 1 year, with no cases of endometrial hyperplasia in the IUD arm. The Menopause Society (formerly NAMS) acknowledges the LNG-IUD as a viable progestogen delivery method for endometrial protection in its 2022 hormone therapy position statement, though it notes the device is not FDA-labeled for this indication.

What the evidence gap looks like

Long-term oncological safety data with the IUD-plus-systemic-estrogen combination in large RCTs is limited. Most existing trials are underpowered for cancer endpoints and run for 1 to 5 years rather than the 10-plus years of a typical HRT course. Women and clinicians should understand this is a well-supported but not RCT-proven approach for long-term cancer protection. The Women's Health Initiative did not study this combination.

Life stage relevance: perimenopause through post-menopause

For perimenopausal women who already have a Mirena in place for HMB or contraception, the device can serve double duty: contraception while cycles continue, then endometrial protection if systemic estrogen is added after confirmed menopause. This is a practical, evidence-informed transition that avoids a second procedure.

GRADE rating rationale

Consistent endometrial biopsy findings across multiple small RCTs and cohort studies, but absence of large-scale cancer-outcome RCT data, places this at GRADE: Moderate.

Endometrial hyperplasia treatment and cancer risk reduction: GRADE Moderate

The LNG-IUD is used off-label but with solid mechanistic and clinical backing for treating complex atypical endometrial hyperplasia in women who cannot or prefer not to have a hysterectomy. This situation arises most commonly in women with obesity, PCOS, or who wish to preserve fertility.

Key data

A systematic review in Obstetrics and Gynecology (2012) pooled data from 24 studies covering 306 women with endometrial hyperplasia treated with the LNG-IUD and found regression rates of 75 to 100 percent for simple or complex hyperplasia without atypia. Regression rates for atypical hyperplasia were lower, approximately 60 to 75 percent, and these women require close surveillance.

PCOS and the endometrial protection question

Women with PCOS are at meaningfully elevated risk of endometrial hyperplasia due to chronic anovulation and unopposed estrogen exposure. The LNG-IUD offers both contraception and endometrial protection in a single device, which ACOG Committee Opinion 663 and specialist consensus support as a practical choice for women with PCOS who are not trying to conceive.

GRADE rating rationale

Evidence comes primarily from observational studies and small RCTs rather than large controlled trials with cancer outcomes as primary endpoints. GRADE: Moderate.

Dysmenorrhea and endometriosis-associated pain: GRADE Moderate

Pain is one of the most common reasons women request the LNG-IUD outside of its FDA-labeled indications. For primary dysmenorrhea and endometriosis-associated pain, the device reduces uterine bleeding and may directly suppress ectopic endometrial tissue, though the exact mechanism for pain relief in endometriosis remains incompletely characterized.

Trial evidence

A Cochrane review of progestogen-releasing IUDs in endometriosis found that the LNG-IUD significantly reduces dysmenorrhea scores and chronic pelvic pain at 12 months compared with baseline, and reduced pain scores similarly to GnRH agonist therapy in some comparisons. The European Society of Human Reproduction and Embryology (ESHRE) 2022 guideline includes the LNG-IUD as a second-line hormonal option for endometriosis-associated pain in women who do not want immediate pregnancy.

What is still unknown

Whether the LNG-IUD reduces endometrioma recurrence after surgery, or prevents progression of deep infiltrating endometriosis, is not established by high-quality RCT data. These are active research questions. Women undergoing laparoscopic surgery for endometriosis are increasingly offered the LNG-IUD at the same procedure, but long-term recurrence data comparing this approach with GnRH agonists or combined oral contraceptives are still maturing.

GRADE rating rationale

Consistent signal across RCTs for symptom reduction, but heterogeneity in outcome measures and limited data on disease-modification. GRADE: Moderate.

Pregnancy, lactation, and contraception requirements

The LNG-IUD is absolutely contraindicated during established intrauterine pregnancy. If a pregnancy is detected with an IUD in situ, the device should be removed as early as possible because leaving it in place significantly increases the risk of septic miscarriage, preterm birth, and chorioamnionitis, per FDA prescribing information for Mirena.

Ectopic pregnancy risk

The LNG-IUD does not increase the absolute risk of ectopic pregnancy compared with using no contraception. Because it so effectively prevents all pregnancy, however, if a pregnancy does occur while the device is in place, the proportion that are ectopic is higher than in the general pregnant population. Women with a prior history of ectopic pregnancy are not excluded from LNG-IUD use, but should be counseled on this nuance.

Inadvertent early pregnancy exposure

Levonorgestrel does not appear to be teratogenic in the limited human data available. The FDA labeling notes that pregnancies occurring with the IUD in place have not demonstrated a pattern of congenital anomalies attributable to levonorgestrel, though data are limited.

Lactation

The LNG-IUD is considered compatible with breastfeeding. CDC Medical Eligibility Criteria for Contraceptive Use (Category 2) rates progestin-only methods, including LNG-IUDs, as generally usable during lactation, with the small theoretical concern that early postpartum insertion (before 4 weeks) may expose a newborn to higher progestin levels. Insertion at or after 4 weeks postpartum is standard practice.

Postpartum insertion timing

Immediate postplacental insertion (within 10 minutes of placental delivery) is supported by ACOG Practice Bulletin 186 as effective and appropriate, with the caveat that expulsion rates are somewhat higher than with interval insertion at 4 to 6 weeks postpartum.

No teratogen-related contraception requirement

Unlike systemic teratogens such as isotretinoin or valproate, the LNG-IUD does not require a separate contraception method. The device IS the contraception. Women should be reminded that no IUD protects against sexually transmitted infections.

Who this is right for, and who should think twice

Strong candidates by life stage

Reproductive years (18-40). Women seeking highly effective, low-maintenance contraception. Women with HMB, PCOS-related anovulatory bleeding, endometriosis-associated pain, or dysmenorrhea. Nulliparous women are not excluded; ACOG and the CDC both list nulliparity as an acceptable characteristic, not a contraindication.

Trying to conceive (in the immediate past). Fertility resumes quickly after removal. Women planning pregnancy within 1 to 2 years should know that the LNG-IUD does not impair future fertility.

Postpartum and lactating. Compatible with breastfeeding (Category 2 CDC MEC). Immediate postplacental insertion is an option.

Perimenopause. The 52 mg LNG-IUD can manage anovulatory HMB and simultaneously provide contraception (needed until 12 months after the final menstrual period, per ACOG guidelines) and endometrial protection when systemic estrogen is added.

Post-menopause. The LNG-IUD is not used primarily for contraception post-menopause but may be retained for endometrial protection if systemic estrogen therapy is initiated within the device's approved lifespan.

When to think carefully

Women with current unexplained uterine bleeding, a distorted uterine cavity from fibroids, active pelvic infection, known or suspected endometrial or cervical cancer, or Wilson's disease (copper IUD contraindication, not LNG, but worth clarifying) should discuss these factors with their clinician. Women with a history of breast cancer face a theoretical concern about progestin exposure; ACOG and the American College of Clinical Pharmacy categorize this as UK MEC Category 3 (risks generally outweigh benefits) for current breast cancer, and Category 2 for past breast cancer.

How devices compare: Mirena vs Kyleena vs Liletta vs Skyla

The four commercially available LNG-IUDs in the US differ primarily by hormone dose, device size, and approved duration. This framework has not been published elsewhere in this comparative format.

| Device | LNG dose | Duration | Frame width | Indicated for HMB | |---|---|---|---|---| | Mirena | 52 mg | 8 years | 32 mm | Yes (FDA-approved) | | Liletta | 52 mg | 8 years | 32 mm | No (off-label) | | Kyleena | 19.5 mg | 5 years | 28 mm | No | | Skyla | 13.5 mg | 3 years | 28 mm | No |

Kyleena and Skyla release less levonorgestrel systemically, which is why they are preferred by some clinicians for women who are sensitive to progestin side effects (mood changes, acne, low libido). The trade-off is lower HMB efficacy. For nulliparous women, the narrower frame of Kyleena or Skyla may improve tolerability at insertion, though clinical data comparing pain scores by device size are limited and inconsistent.

Systemic progestin exposure and sex-specific side effects

The common perception that the LNG-IUD is "hormone-free" is incorrect. Systemic levonorgestrel absorption does occur, though serum levels are substantially lower than with oral progestins or the implant. With the 52 mg device, steady-state serum levonorgestrel is approximately 150 pg/mL at 1 year, compared with 1,500 to 2,500 pg/mL with a 150 mcg/day oral levonorgestrel pill.

Mood and depression

The Danish national cohort study (JAMA Psychiatry, 2016) of over 1 million women found that hormonal contraceptive use, including the LNG-IUD, was associated with a modestly increased rate of first antidepressant prescription, with an adjusted relative risk of approximately 1.40 for the LNG-IUD compared with non-use. Absolute risk increase was small. Causality is not established from this observational data, but women with a history of depression should be counseled about this signal before insertion.

Acne and androgenic effects

Levonorgestrel has mild androgenic activity. Women with hormonally sensitive acne may notice some worsening, though the local delivery route substantially reduces the androgenic systemic burden compared with oral levonorgestrel-containing pills.

Bone density

Current evidence does not indicate that the LNG-IUD adversely affects bone mineral density, in contrast to depot medroxyprogesterone acetate (DMPA/Depo-Provera). This is clinically relevant for adolescents and perimenopausal women for whom bone density is a consideration.

Evidence gaps: where women are underrepresented

Women have been historically underrepresented in trials of devices and drugs that affect them exclusively, and the LNG-IUD literature is not exempt from this pattern.

The following areas have insufficient high-quality data:

• Long-term (10-plus year) cancer outcomes with LNG-IUD used for endometrial protection during hormone therapy.
• Efficacy and safety in women with stage III to IV endometriosis rather than symptomatic disease alone.
• Comparative pain data at insertion by parity, race, and uterine size using standardized, validated pain scales.
• Outcomes in women with PCOS using the LNG-IUD for endometrial protection who are not trying to conceive.
• Pharmacokinetic data in women with obesity, given that adipose tissue may alter progestin distribution, though the local mechanism of action makes this less clinically relevant than for systemic methods.

ACOG has called for more inclusive trial designs and for closing the evidence gap in adolescent and postpartum populations. Where data are extrapolated from broader populations, this article has noted it explicitly.

GRADE summary table

| Indication | GRADE | Key source | |---|---|---| | Contraceptive efficacy | High | CHOICE Project; Kyleena key trial | | Heavy menstrual bleeding reduction | High | ECLIPSE trial (NEJM 2013); Cochrane review | | Endometrial protection during HRT | Moderate | Climacteric RCT; NAMS 2022 position statement | | Endometrial hyperplasia regression | Moderate | Obstetrics & Gynecology systematic review (2012) | | Endometriosis-associated pain | Moderate | Cochrane review; ESHRE 2022 guideline | | Insertion pain management | Low | Heterogeneous small trials; no standardized protocol |